Predictive Oncology Inc. (POAI)
NASDAQ: POAI · Real-Time Price · USD
0.8749
-0.0401 (-4.38%)
At close: Aug 29, 2025, 4:00 PM
0.8875
+0.0126 (1.44%)
After-hours: Aug 29, 2025, 7:59 PM EDT
Predictive Oncology Revenue
Predictive Oncology had revenue of $2.68K in the quarter ending June 30, 2025, a decrease of -96.01%. This brings the company's revenue in the last twelve months to $1.66M, up 71.65% year-over-year. In the year 2024, Predictive Oncology had annual revenue of $1.62M, down -0.24%.
Revenue (ttm)
$1.66M
Revenue Growth
+71.65%
P/S Ratio
3.86
Revenue / Employee
$69,362
Employees
24
Market Cap
9.53M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.62M | -3.88K | -0.24% |
| Dec 31, 2023 | 1.63M | 122.24K | 8.12% |
| Dec 31, 2022 | 1.51M | 84.78K | 5.97% |
| Dec 31, 2021 | 1.42M | 168.41K | 13.45% |
| Dec 31, 2020 | 1.25M | -159.29K | -11.28% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
POAI News
- 12 days ago - PREDICTIVE ONCOLOGY INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Predictive Oncology Inc. - POAI - GlobeNewsWire
- 18 days ago - Predictive Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 weeks ago - Predictive Oncology Announces $10M Share Purchase Agreement in Partnership with Yorkville Advisors to Advance AI-Driven Drug Discovery and Repurposing - GlobeNewsWire
- 2 months ago - Predictive Oncology Develops Functional 3D Organoid Models Exclusively for Labcorp - GlobeNewsWire
- 3 months ago - Court Denies Renovaro Motion for an Expedited Trial in July - GlobeNewsWire
- 3 months ago - AI Meets Genomics: Predictive Oncology Breakthrough Coincides with Regeneron's $256M 23andMe Acquisition - GlobeNewsWire
- 3 months ago - Predictive Oncology Inc. Issues Shareholder Letter Titled, "Revolutionizing Medicine: AI-Driven Biomarker and Drug Discovery for Precision Health" - GlobeNewsWire
- 3 months ago - Predictive Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire